Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
Open Access
- 10 October 2012
- journal article
- early detection-and-diagnosis
- Published by Wiley in International Journal of Cancer
- Vol. 132 (10), 2349-2358
- https://doi.org/10.1002/ijc.27894
Abstract
Radioembolization therapy (RE) is an efficient locoregional treatment for liver metastases from colorectal cancer. Serum biomarkers involved in immunogenic cell death are potentially valuable for early predicting therapy response and estimating prognosis. In a prospective observation study, blood samples were taken from 49 consecutive colorectal cancer patients with extensive hepatic metastases before, 24 and 48 hr after RE. Serum levels of high mobility group box 1 (HMGB1), receptor of glycation end products (RAGE) and activity of desoxyribonuclease were compared with response to therapy regularly determined radiologically 3 months after therapy and with overall survival. Serum levels of HMGB1 were increased already 24 hr after RE, while RAGE levels were decreased and DNAse remained unchanged. In radiological staging, 35 patients demonstrated disease progression while 14 patients had stable disease or remission. Serum HMGB1 levels 24 hr after RE were significantly higher in progressive than in nonprogressive patients while for RAGE and DNAse no difference was observed between the response groups. Concerning overall survival, high pretherapeutic (0 hr) and 24 hr levels of HMGB1 were associated with poor outcome. Multivariate analysis including HMGB1, tumor, liver and inflammation markers revealed HMGB1 and CRP as independent prognostic parameters. HMGB1 is a valuable serum biomarker for early estimation of therapy response and prognosis in colorectal cancer patients with liver metastases undergoing RE therapy.This publication has 45 references indexed in Scilit:
- Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancerJournal of Medical Imaging and Radiation Oncology, 2010
- Radioembolization of Liver Tumors With Yttrium-90 MicrospheresSeminars in Nuclear Medicine, 2010
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole liversInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancerJournal of Surgical Oncology, 2004
- Treatment of liver metastases, an update on the possibilities and resultsEuropean Journal of Cancer, 2002
- Partial irradiation of the liverSeminars in Radiation Oncology, 2001
- Radiofrequency Ablation of Unresectable Hepatic Malignancies: Lessons LearnedThe Oncologist, 2001
- Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapyPhysics in Medicine & Biology, 2001
- Haematogenous metastastic patterns in colonic carcinoma: An analysis of 1541 necropsiesThe Journal of Pathology, 1986